ARCHIVES

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

NCI Funded Over 4,500 Grants Last Year, Half Its $3B Budget.

January 19, 2001

Healy Attacks Scripps-Sandoz Research Deal, Rep. Wyden Asks For HHS Investigation

March 19, 1993

In Brief: Congress Asked To Investigate Dieldrin Danger; Harvard’s Rosenberg To Be NCI Surgery Chief

April 5, 1974

In Brief: New Cancer control Program On Schedule; NCI Expects 10-15CCRU, 30-40 CCSP Applications

July 2, 1982

NCI Cooperative Group, Cancer Center Trials Listed

September 28, 2007

Totality Of Evidence Causes Concern About New Findings.

December 7, 2007